Molnupiravir clinical trials
Molnupiravir is named as an intervention in 4 current clinical trials in our Brazil, France, Spain, Italy, Netherlands, UK, USA, Germany, Poland, Mexico, Japan, South Korea, Taiwan, Australia, India, Belgium, Sweden and Portugal registers. 4 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is University of Oxford (3). The most-studied condition is Coronavirus Disease (COVID-19).
What health systems spend on Molnupiravir
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Molnupiravir works
All drug targets →- COVID-19Phase 3
- COVID-19–associated multisystem inflammatory syndrome in childrenPhase 3
- Orthomyxoviridae infectious diseasePhase 3
- Dengue diseasePhase 2
- Respiratory syncytial virus infectious diseasePhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4650320, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 10737, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
NICE appraisals of Molnupiravir
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 1 technology appraisal of Molnupiravir. 1 is current, and 1 of it recommends it for at least some patients.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Molnupiravir for treating COVID-19 NICE TA1056 | Optimised | 16 Apr 2025 Updated 26 Feb 2026 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Molnupiravir
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Molnupiravir
4 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Randomised Evaluation of COVID-19 Therapy
NCT04381936 · ClinicalTrials.gov ↗ · Pneumonia
|
Phase 3 | Recruiting | University of Oxford | India, France, Spain, Italy, Netherlands, Belgium, Sweden, Portugal |
|
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
NCT06667700 · Coronavirus Disease (COVID-19)
|
Phase 3 | Recruiting | Merck Sharp & Dohme LLC | UK, USA, Germany, France, Spain, Italy, Netherlands, Poland, Brazil, Mexico, Japan, South Korea, Taiwan, Australia |
|
Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)
NCT05041907 · ClinicalTrials.gov ↗ · COVID-19
|
Phase 2 | Recruiting | University of Oxford | Brazil |
|
A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza
NCT05648448 · ClinicalTrials.gov ↗ · Influenza, Influenza, Human
|
Phase 2 | Recruiting | University of Oxford | Brazil |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Molnupiravir across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Supply shortages
- Molnupiravir CapsuleUS (FDA) · Resolved · updated 20 Oct 2026
Conditions studied with Molnupiravir
5 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| University of Oxford | 3 |
| Merck Sharp & Dohme LLC | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Molnupiravir trials
How many clinical trials are testing Molnupiravir?
4 current trials in our Brazil, France, Spain, Italy, Netherlands, UK, USA, Germany, Poland, Mexico, Japan, South Korea, Taiwan, Australia, India, Belgium, Sweden and Portugal registers name Molnupiravir (also registered as MK-4482) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Molnupiravir trials recruiting patients?
Yes. 4 of the 4 trials are recruiting: 3 with sites in Brazil, 2 with sites in France, 2 with sites in Spain, 2 with sites in Italy, 2 with sites in Netherlands, 1 with sites in UK, 1 with sites in USA, 1 with sites in Germany, 1 with sites in Poland, 1 with sites in Mexico, 1 with sites in Japan, 1 with sites in South Korea, 1 with sites in Taiwan, 1 with sites in Australia, 1 with sites in India, 1 with sites in Belgium, 1 with sites in Sweden and 1 with sites in Portugal. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Molnupiravir clinical trials?
University of Oxford (3) and Merck Sharp & Dohme LLC (1). The number in brackets is how many trials each organisation leads.
Is there a Molnupiravir shortage?
The registers we track list 1 entry for Molnupiravir: US FDA: resolved. Shortages are product- and country-specific; check with a pharmacist.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Molnupiravir works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Molnupiravir works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Molnupiravir (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.